PMC55 IMPACT OF THE FDA DRAFT GUIDANCE ON PATIENT REPORTED OUTCOMES (PRO) LABEL CLAIMS FOR APPROVED DRUG PRODUCTS IN THE US- HAS IT MADE A DIFFERENCE?
Abstract
Authors
M Mordin M Clark C Siersma K Copley-Merriman A Gnanasakthy
M Mordin M Clark C Siersma K Copley-Merriman A Gnanasakthy
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now